secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001558370-23-001642
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma Q2 FY2023 revenue $26.3M (+14% YoY); second consecutive positive adjusted EBITDA $0.7M
--------------------------------------------------------------------------------

- Net revenue $26.3M, up 14% YoY; Rx segment $18.0M (+23%) driven by 95% growth in pediatric products.
- Adjusted EBITDA positive $0.7M vs $(7.6)M loss in year-ago quarter; second consecutive positive quarter.
- Net loss $(6.7)M ($2.15 per share) improved from $(11.5)M ($8.74 per share) in Q2 FY2022.
- Gross margin expanded to 66% from 53% YoY; suspension of clinical programs expected to save over $20M.
- Extended interest-only period on Avenue loan to Jan 2024; 1-for-20 reverse stock split regained Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/0001558370-23-001642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/aytu-20230221x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer